Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol - Full Text View

Sponsor:	University of Dundee
Information provided by:	University of Dundee
ClinicalTrials.gov Identifier:	NCT00830882

Purpose

The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.

Condition	Intervention	Phase
Asthma	Drug: levosalbutamol Drug: racemic salbutamol Drug: placebo	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics.

Resource links provided by NLM:

MedlinePlus related topics: Allergy Asthma Potassium

Drug Information available for: Albuterol Levalbuterol hydrochloride Albuterol sulfate Levalbuterol tartrate

U.S. FDA Resources

Further study details as provided by University of Dundee:

Primary Outcome Measures:

Methacholine challenge [ Time Frame: Before and 30 mins after drug administration, and after 2 weeks of chronic treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Salbutamol pharmacokinetics [ Time Frame: over 30 minutes after drug administration, one day 1 and 14 of a 2 week study period ] [ Designated as safety issue: No ]
Spirometry [ Time Frame: before and 30 mins after drug administration, at single dose and after 2 weeks chronic dosing ] [ Designated as safety issue: No ]
potassium [ Time Frame: before and 30 mins after drug administration, at single dose and after 2 weeks chronic dosing ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	30
Study Start Date:	January 2009
Estimated Study Completion Date:	January 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1:levosalbutamol 2 puffs four times a day for 2 weeks	Drug: levosalbutamol 2 puffs four times a day for 2 weeks Other Name: levosalbutamol
Active Comparator: 2: racemic salbutamol 2 puffs four times a day for 2 weeks	Drug: racemic salbutamol 2 puffs four times a day for 2 weeks Other Name: ventolin
Placebo Comparator: 3: Placebo 2 puffs four times a day for 2 weeks	Drug: placebo 2 puffs four times a day for 2 weeks Other Name: placebo to salbutamol

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent
Methacholine responsive PC20< 4 mg/ml
>1dd change in methacholine PC20 after the administration of racemic Salbutamol.
Male or female 18-65
Informed Consent
Ability to comply with the requirements of the protocol

Exclusion Criteria:

Severe asthmatics as defined by an FEV1≤ 60% or PEF variability > 30% or with continual daytime or nocturnal symptoms.
The use of oral corticosteroids within the last 3 months.
Recent respiratory tract infection (2 months).
Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and active pulmonary tuberculosis.
Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
Any significant abnormal laboratory result as deemed by the investigators
Pregnancy, planned pregnancy or lactation
Known or suspected contra-indication to any of the IMP's
Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00830882

Contacts

Contact: karine L Clearie, MBBS, MRCP	01382 496440 ext 36440	k.clearie@dundee.ac.uk
Contact: Brian J Lipworth, MBchB	01382496440 ext 36440	brianlipworth@googlemail.com

Locations

United Kingdom
Asthma and Allergy Research Group	Recruiting
Dundee, Angus, United Kingdom, DD1 9SY
Contact: Karine L Clearie, MBBS 01382496440 ext 36440 k.clearie@dundee.ac.uk
Contact: Brian J Lipworth, MBchB 01382496440 ext 36440 brianlipworth@googlemail.com

Sponsors and Collaborators

University of Dundee

Investigators

Principal Investigator:	Karine L Clearie, MBBS, MRCP	Asthma and Allergy Research Group
Study Director:	Brian J Lipworth, MBchB	Asthma and Allergy Research Group

More Information

No publications provided

Responsible Party:	Dr Karine Clearie, Asthma and Allergy Research Group
ClinicalTrials.gov Identifier:	NCT00830882 History of Changes
Other Study ID Numbers:	NAI007
Study First Received:	January 27, 2009
Last Updated:	January 27, 2009
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Dundee:

asthma
levosalbutamol
genotype
bronchoprotection

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Albuterol
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs

Pharmacologic Actions
Therapeutic Uses
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on February 09, 2012